# 1. Financial Performance ## A. Key Figures * Operating Income: **INR117.2 Cr** Q3 FY26 * EBITDA: ₹5.7 Cr (4.6% margin) * **PAT:** **-₹0.02 Cr** (-0.01% margin) ## B. Margins & Profitability * **Gross Margin Trend:** Gross margin improved YoY by over 50 bps despite a quarterly decline, driven by cost discipline amid a **7% rise in raw material costs**. * **Margin Confusion Clarified:** Prior indication of 7% gross margin increase was misinterpreted; actual improvement was in input costs, not margin. ## C. Balance Sheet * **Promoter Pledging:** Recent promoter shareholding reduction due to invocation of **₹77 Cr** worth of pledged shares, representing less than 10% of total capital and ~26% of promoter stake; no further invocation anticipated. * **Debt Position:** Balance sheet remains conservatively financed with **no long-term debt**, limited to working capital obligations. --- # 2. Segment & Product Performance ## A. Key Figures * O&M Revenue: ₹13.35 Cr (Q3 FY26) * **API Revenue:** **₹14.13 Cr** (Q3 FY26) * **Total Consolidated Revenue:** **₹117 Cr** (Q) * **MCC Volume:** **10,000 MT** (9M) vs. **13,500 MT** capacity (9M) * EBITDA Margin: Below 5% (this quarter) vs. ~7% last two to three quarters ## B. MCC Segment * **Resilient Core Demand:** MCC continues to see strong demand and **pricing stability with slight increases**, despite supply constraints limiting revenue share. * **High Gross Margin Resilience:** MCC gross margins remain robust at **~40%**, reflecting pricing power and product stickiness amid production bottlenecks. * **Capacity Constraints Weigh on Output:** Reduced MCC revenue share attributed to **production and supply constraints**, not demand; volume at ~74% of 9M capacity. ## C. O&M Segment * **Stable Services Platform:** O&M delivers consistent performance with **~22% gross margin**, reinforcing its role as a scalable, margin-accretive vertical. * **Value-Add Processing Model:** Involves **n-1 stage procurement** and final processing for export—**not pure trading**—supporting margin integrity. ## D. API Segment * **Low-Margin Contributor:** API segment reports **~10% gross margin**, the lowest among segments, with no forward guidance provided for FY27. --- # 3. Capacity & Expansion ## A. Key Figures * **Current Capacity:** **18,000 MTPA** cellulose-based excipients (Dahej: 9,882 MTPA · Jhagadia: 8,118 MTPA) * **Utilization Rate:** **70–73%** across existing units * **Export Mix:** **62%** of production ## B. Dahej Expansion * **Strategic Scale-Up:** Major capacity expansion underway at Dahej SEZ, including a **12,000 MTPA MCC unit** and a **1,800 MTPA CCS disintegrant facility**, both targeting commissioning in **Q3 FY27**. * **Operational Pivot:** Management has fully shifted focus to Dahej, prioritizing capex efficiency and ramp-up; **no near-term plans to revive Hyderabad plant** despite its 6,000 MTPA legacy capacity. * **Portfolio Diversification:** New CCS facility aligns with customer demand for integrated MCC and disintegrant supply, enhancing value-added product offerings. ## C. Hyderabad Transition * **Site Complexity:** Hyderabad’s 2-acre facility remains unresolved due to **legal and regulatory constraints**, with potential for non-industrial redevelopment limiting operational revival prospects. ## D. Utilization Rates * **Near-Term Headwinds:** Capacity utilization temporarily impacted by **multiple audits**, though production is expected to normalize in **Q4 and beyond**. * **Long-Term Absorption:** New Dahej capacities expected to absorb overheads and support full operational normalization by **FY27**. --- # 4. Supply Chain & Costs ## A. Key Figures * **Custom Duty Impact:** **Additional financial burden** due to duties on imported wood pulp; impact deemed transient with no unforeseen duties expected * **Raw Material Redirection:** **All materials** previously for Hyderabad now redirected to **Dahej and Jhagadia**; no new procurement for Hyderabad pending regulatory clarity ## B. Raw Material Flow * **Supply Disruptions:** Raw material consumption inefficiencies rose post-fire due to logistical and transfer challenges, affecting input availability and cost control. * **Duty Headwind Resolved:** Custom duty outflow was a one-time cost; imported pulp has arrived and future imports await facility readiness, removing near-term duty risk. * **Procurement Halt:** Hyderabad procurement remains suspended, with full supply chain rerouted to Gujarat plants, signaling prolonged operational shift. ## C. Overhead Redistribution * **Cost Absorption Pressure:** Hyderabad’s overheads reallocated across active units, increasing operational costs and weighing on margins. ## D. Transportation Costs * **Elevated Logistics Spend:** Significant transportation and landing costs incurred in moving raw materials to Dahej and Jhagadia, adding to cost headwinds. --- # 5. R&D & Regulatory Progress ## A. R&D & Regulatory Strategy * **Headline:** Strategic focus on regulated markets through compliance-led R&D, with Metformin already CEP-approved and multiple filings under review. * **Headline:** **Six CEP filings** targeted from the new Hyderabad API R&D facility, building on **six prior filings**, though no timeline or revenue impact guidance was provided. * **Headline:** Commercialization of CEP-approved APIs awaits **customer seeding and stability testing**, delaying near-term revenue visibility. ## B. Cystic Fibrosis API Development * **Headline:** High confidence in securing a commercial partner for Cystic Fibrosis API, supported by positive R&D outcomes and projected **favorable margins**. * **Headline:** Emerging therapy area with no publicly known competitors, positioning the company as an early entrant in a niche segment. ## C. Quality & Compliance Engagement * **Headline:** Active participation in national cGMP initiatives and sustained investments in quality systems to support scalable, compliant growth. --- # 6. Operational & Regulatory Risks ## A. Key Figures * ₹70 Cr total potential recovery (₹48 Cr fixed assets + ₹4 Cr inventory + ₹25 Cr BI) * EBITDA Margin: 4.6% post-incident (down from ~20%) ## B. Fire Incident Impact * **Operational Recovery Underway:** Organizational improvements in EHS, oversight, and operating discipline are ongoing and prioritized to restore stability and ensure customer commitments. * **Production Disruptions Continue:** A temporary slowdown persists across units due to internal audits and safety protocol redefinition following the Hyderabad fire. * **Margin Pressure Intensified:** Reduced output from the incident has strained overhead absorption, contributing to sharply lower profitability versus prior levels. ## C. Insurance Claims * **Partial Payout Expected Soon:** An ad hoc recovery of **₹20–25 Cr** anticipated by March 31, covering initial losses, with fixed asset and inventory claims to follow. * **Business Interruption Claim Delayed:** BI component of **₹25 Cr** will be processed later due to 12-month policy term; full settlement remains pending documentation. ## D. Legal Proceedings * **No Executive Disruption Expected:** No further legal action anticipated against MD & CEO Amit Raj Sinha; case expected to last 1–5 years but without risk of re-arrest. * **Limited Disclosure Due to Sub Judice Status:** Management restricted in commenting further on the ongoing legal matter. --- # 7. Guidance & Outlook ## A. Key Figures * Revenue Guidance: ~25% prior growth target · INR 250 Cr from Cystic Fibrosis API (~12 months post-development) * **Margin Guidance:** **Double-digit EBITDA margins** expected from FY28 onward · Normalization expected by FY28 ## B. Revenue Forecast * **Growth Trajectory:** Outlook remains positive over the medium term despite near-term headwinds, with diversified portfolio and **clear demand visibility** underpinning confidence in sustainable growth. * **Capacity Ramp-Up:** FY27 to see partial benefit from expanded capacities, with full operational and growth normalization anticipated by **FY28**. * **New Revenue Stream:** Cystic Fibrosis API to contribute **INR 250 Cr** annually post-commercialization, marking a significant step in specialty API expansion. ## C. Margin Recovery * **Earnings Normalization:** Margin recovery on track, with return to **normal revenue and earnings levels** expected by Q4 of current year and stabilization in H1 of next fiscal. * **Margin Expansion Path:** EBITDA margins set to improve from **FY28 onwards**, supported by operational normalization and mix optimization, though FY27 remains transitional. ## D. Capex Plans * **Strategic Expansion:** Capex focused on **Dahej and CCS facility development**, capacity build-out, and vertical integration to support long-term profitability. * **Flexible Funding Approach:** Future capex to be funded via **equity or debt**, with final decision pending board approval; no specific quantum disclosed yet.